You are here

Thomas Sundberg


Johannessen L, Sundberg TB, O’Connell DJ, et al. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nat Chem Biol. 2017;13(10):1102-1108.

Sundberg TB, Liang Y, Wu H, et al. Development of chemical probes for investigation of salt-inducible kinase function in vivo. ACS Chem Biol. 2016;11(8):2105-2111.

Sundberg TB, Choi HG, Song JH et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci USA. 2014 Aug 26;111(34):12468-73.


Thomas Sundberg, Ph.D.

Thomas Sundberg is a senior research scientist I with expertise in chemical biology and translational immunology in the  Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. The focus of his work at CDoT is developing therapies that enhance anti-inflammatory functions of immune cells with a particular focus on small molecule approaches to upregulating the key anti-inflammatory cytokine IL-10. As part of these efforts, he serves as a project lead for a collaboration with a biopharmaceutical industry partner developing first-in-class therapies for autoimmune/auto-inflammatory disorders.

Sundberg joined the Broad Institute upon completion of his postdoc in 2012 and was selected as an Exceptional Performer during the Broad Institute’s 2012-2013 performance management cycle. He received a Ph.D. in chemical biology from the University of Michigan at Ann Arbor and upon its completion in 2010 was awarded the American Cancer Society Postdoctoral Fellowship at Yale University; in the course of the fellowship, he studied new chemical biology approaches to targeted protein degradation. Sundberg also holds a B.A. in chemistry from the University of Texas at Austin.

Contact Thomas Sundberg via email at

February 2018